Catégorie : Biotech

ALGENSCRIBE

by jbertholdin Biotech, Pharma

ALGENSCRIBE

About the company

Algenscribe operates in the field of Gene Editing: the company is developing a new platform for Gene Replacement with its first applications in Gene Therapy and Oncology.

About the solution

The aim is to achieve the full potential of Gene Editing for Gene Replacement. Algenscribe’s technologies address two major constraints of the field: the number of cells edited is significantly increased, while certain undesirable effects are reduced.

Website
Key information

–  Therapeutic areas: Gene Editing, Gene Therapy, Oncology

–  Based in: Gif sur Yvette & Nice (FRANCE)

–  Employees: 1 – 10

–  Created in: 2022

XENOTHERA

by jbertholdin Biotech, Pharma

XENOTHERA

About the company

XENOTHERA is a clinical stage biotech company developing First-In-Class drugs mainly in oncology and hematology.

Their disruptive immunotherapy, based on a patented platform of Glyco-Humanized Polyclonal Antibodies (GH-pAb), addresses major unmet medical needs, especially in solid and liquid tumors. Accelerated development is made possible due to scaled-up commercial grade industry, regulatory and clinical expertise, and in-house bioproduction facility.

About the solution

XENOTHERA develops two main assets: LIS1, in Peripheral T-cell lymphoma (First Patient expected Q2 2024) and in Solid Organ Transplantation (confirmatory pivotal trial in preparation) and XON7, a pan-cancer GH-pAb targeting solid tumors, currently in Phase I/II.

Website
Key information

–  Therapeutic areas: Oncology, Acute Graft rejection

–  Based in: Nantes (FRANCE)

–  Employees: 11 – 50

–  Created in: 2014

SYNDIVIA

by jbertholdin Biotech, Pharma

SYNDIVIA

About the company

Syndivia is dedicated to enhancing treatment options for patients with solid tumors. They specialize in utilizing their proprietary and unique GeminiMab™ technology — the first and only hinge-region Cys229 site-specific ADC technology applicable to native monoclonal antibodies. Specifically, they take advantage of the distinctive GeminiMab™-DAR1 ADCs, which offer improved antitumor efficacy and reduced toxicity.

About the solution

The key technology behind Syndivia’s unique site-specific approach is GeminiMab™, the first and only technology for hinge-region site-specific conjugation (2xCys229), enabling unprecedented efficiency and scope in creating site-specific DAR1 ADCs.

Their proprietary candidates include:

1. SDV2102: GeminiMab anti-PSMA ADC (mCRPC, GBM, HCC)

2. SDV2103: GeminiMab anti-Trop2 ADC (NSCLC)

Website
Key information

–  Therapeutic areas: Antibody-drug-conjgutes, Oncology

–  Based in: Strasbourg (FRANCE)

–  Employees: 1 – 10

–  Created in: 2014

FIRALIS MOLECULAR PRECISION

by jbertholdin Biotech, Pharma

FIRALIS MOLECULAR PRECISION

About the company

Firalis Molecular Precision (FMP), established in 2019 and rooted in the Firalis Group, operates as a leading Contract Research Organization (CRO) from Huningue, France.

Specialized in biomarker discovery and multi-omic analysis (genomics, proteomics, metabolomics), FMP accelerates precision medicine by improving diagnostics, understanding disease mechanisms, and evaluating drug efficacy. With advanced laboratories and a dedicated team of over 55 experts, FMP supports biotech and pharma companies globally, offering a suite of services that span pre-clinical to clinical trials, thus playing a pivotal role in advancing healthcare innovations.

About the solution

Firalis Molecular Precision (FMP) is at the forefront of the multi-omics revolution bringing progress and innovation to the biopharmaceutical industry. By harnessing advanced -omics technologies and bioinformatics, they excel in identifying promising therapeutic targets and enhancing the drug development process for greater speed and reliability. Their state-of-the-art multi-omics solutions facilitate precise, high-throughput genomics, transcriptomics, and proteomics, leading to pioneering healthcare breakthroughs.

Website
Key information

–  Therapeutic areas: Neurology, Oncology, Immunology  

–  Based in: Huningue (FRANCE) & Cambridge (USA)

–  Employees: 51 – 200

–  Created in: 2016

HERMERION THERAPEUTICS

by jbertholdin Biotech, Medtech, Pharma

HERMERION THERAPEUTICS

About the company

Hemerion was created in 2020, after more than 10 years of academic research carried out in an INSERM laboratory in association with Lille University Hospital in France. They are developing a first-line treatment for newly diagnosed Glioblastoma (GBM) that integrates with surgery before the administration of adjuvant therapies.

Their mission is to deliver novel therapies that aim at significantly improving the overall survival and quality of life of GBM patients.

Hemerion is an award-winning HealthTech company:

– In 2021 they received the Galien MedStartup Prize for « Best Collaboration in the MedTech and Digital Health » category. The Galien MedStartup fosters, recognizes, and rewards excellence in scientific innovation to improve the state of human health. Since 2013, it supports the international development of the most promising French startups, selected by a world-renowned panel, and connects them with leading American businesses.

– In 2023 they were awarded the Golden Ticket Ipsen Biolabs at the Biotech incubator Hotel Dieu Paris, granting them access to biology laboratories to enable the development of preclinical research in glioblastoma.

About the solution

They are developing a first-in-class therapeutic approach for glioblastoma (GBM), the most common malignant brain tumor in adults with 156,000 new cases worldwide per year. Their strategy is promising to significantly improve GBM care management through its unique properties:

– They combine a photonic device (Heliance® Solution) and a drug (Pentalafen®), a photosensitizing agent, which has a therapeutic effect when illuminated with red light.

– This approach represents a breakthrough one-time intervention enabling the destruction of residual tumor cells, responsible for tumor recurrence, following surgery resection.

– It is harmless for healthy tissues as Pentalafen® preferentially accumulates in tumor cells to selectively destroy them.

All in all, their innovation is a novel and safe mechanism of action significantly improving GBM upfront care management by only adding 30 minutes to the current care workflow. Their solution is a photodynamic therapy approach for GBM patients undergoing surgery and seamlessly fits into any patient continuum of care.

Website
Key information

–  Therapeutic areas: Oncology, Neuro-Oncology, Brain Tumor, Neurosurgery

–  Based in: Lille & Paris (FRANCE)

–  Employees: 11 – 50

–  Created in: 2020

AUROBAC THERAPEUTICS

by jbertholdin Biotech, Pharma

AUROBAC THERAPEUTICS

About the company

AUROBAC THERAPEUTICS is a biopharmaceutical company founded in 2022 as a joint venture by Boehringer Ingelheim, Evotec, and bioMérieux, aiming to develop the next generation of precision medicines and become leaders in the fight against bacterial infections, antimicrobial resistance, and their consequences such as sepsis in acute hospital settings.

Their pipeline stands out for their commitment to tackling the highest unmet medical needs in the fields of AMR, infectious diseases, and their consequences.

They focus on ESKAPE pathogens, particularly gram-negatives such as Pseudomonas aeruginosa, and on acute hospital settings where there are no satisfactory therapeutic options to date, such as Acute Respiratory Infections (HAP, VAP), Sepsis, and/or Septic Shock. New treatment modalities and classes that can be combined with rapid and actionable diagnostics to follow a precision medicine concept are their priorities.

AUROBAC THERAPEUTICS aims to cover the entire value chain of projects, including research and development, clinical trials, registration, and commercialization.

About the solution

They focus all our effort on identifying and developing innovative products with the ability to address clear unmet medical needs associated to bacterial infections and increasing AMR, aligned with viable clinical development plans based on a precision medicine concept.

Website
Key information

–  Therapeutic areas: AMR, Bacterial Infections, Acute Respiratory Infections, Sepsis & Septic Shock

–  Based in: Lyon (FRANCE)

–  Employees: 11 – 50

–  Created in: 2022

LYS THERAPEUTICS

by jbertholdin Biotech, Pharma

LYS THERAPEUTICS

About the company

Lys Therapeutics is a pioneering biotechnology company dedicated to addressing unmet medical needs in patients afflicted with neurovascular or neurodegenerative disorders through a revolutionary approach targeting blood-brain barrier (BBB) dysfunction.

Lys Therapeutics’ approach of targeting neuroinflammation to combat neurodegeneration represents a promising avenue in the quest for effective treatments for these debilitating disorders.

About the solution

In the pathophysiology of various neurological diseases such as stroke, multiple sclerosis, and Parkinson’s disease, hyperactivation of endothelial NMDA receptors (NMDAr) by overexpressed tissue plasminogen activator (tPA) leads to the degradation of tight junctions and subsequent BBB dysfunction. This process allows inflammatory cells and toxic molecules to migrate into the brain parenchyma, triggering severe neuroinflammation and excitotoxicity, which are primary contributors to neurodegeneration.

Lys Therapeutics’ lead compound, LYS241, is a first-in-class monoclonal antibody with a groundbreaking mechanism of action that effectively counters these pathological mechanisms. Specifically, LYS241 acts within blood vessels to prevent the binding of tPA to NMDAr, without interfering with the physiological function of NMDA receptors. By inhibiting this interaction, NMDA receptors can function normally, thereby halting downstream deleterious cellular pathways. As a result, tight junctions are reinstated, endothelial cells regain their healthy state, and BBB function is restored, shielding the brain from further neuroinflammatory and subsequent neurodegenerative cascades.

Website
Key information

–  Therapeutic areas: Neurology, CNS, Neurovascular diseases, Neurodegenerative disorders

–  Based in: Lyon and Caen (FRANCE)

–  Employees: 11 – 50

–  Created in: 2021

ACTICOR BIOTECH

by jbertholdin Biotech, Pharma

ACTICOR BIOTECH

About the company

Acticor Biotech is a clinical stage biopharmaceutical company,a spin-off from INSERM (the French National Institute of Health and Medical Research), which is aiming to develop an innovative treatment for cardiovascular emergencies, including ischemic stroke.

In May 2022, Acticor Biotech presented positive results from its Phase 1b/2a study, ACTIMIS, confirming the safety profile and showing a reduction in mortality and intracerebral hemorrhage in the glenzocimab-treated group in patients with stroke.
The efficacy of glenzocimab is now being evaluated in an international Phase 2/3 study, ACTISAVE, which will include 400 patients, with clinical results expected in Q2 2024.

About the solution

Glenzocimab is a humanized monoclonal antibody fragment (fab) directed against the human platelet glycoprotein GPVI, and a novel antithrombotic drug developed by Acticor-Biotech. Glenzocimab is being developed for use during the acute phase of ischemic stroke as an add-on therapy to thrombolysis, with or without mechanical thrombectomy.

Moreover, since 2020, the action of glenzocimab has also been explored regarding the treatment of Acute Respiratory Distress Syndrome (ARDS) in patients infected with SARS-Cov-2.

Website
Key information

–  Therapeutic areas: Cardiovascular emergencies, Acute ischemic stroke

–  Based in: Paris (FRANCE) dedicated external team in US territory

–  Employees: 11 – 50

–  Created in: 2013

WHITELAB GENOMICS

by jbertholdin Biotech

WHITELAB GENOMICS

About the company

Founded in 2019, backed by Y-Combinator, WhiteLab Genomics stands at the convergence of computer sciences and biology, pioneering the accelerated development of genomic medicines. By leveraging their proprietary technology, WhiteLab Genomics analyzes complex biological data powered by AI to significantly reduce development timelines and mitigate associated risks.

About the solution

Based on exhaustive datasets, the platform provides in-silico simulations to discover and design optimized payloads and vectors. WhiteLab aims to expedite the drug development process, cut costs, and accelerate the delivery of life-saving therapies to the market. The company collaborates with leading pharmaceutical companies such as Sanofi, academic institutions, and innovative biotechnology companies.

Website
Key information

–  Therapeutic areas: solutions are transposable to any therapeutic areas targetable by Cell and Gene therapies.

–  Based in: Paris (FRANCE), Cambridge (USA)

–  Employees: 11 -50

–  Created in: 2019

AFFILOGIC

by jbertholdin Biotech, Pharma

AFFILOGIC

About the company

Affilogic is a private, French biotech company established in 2010. They are specialized in discovering and developing Nanofitins® through collaborations with worldwide industry leaders in the pharmaceutical sector.

About the solution

Nanofitins are small, hyperstable affinity proteins, which can be designed as targeted inhibitors, or as vectors for specific addressing of cells and tissues. Affilogic follows the science to any therapeutic area as long as an innovative Nanofitin-based biotherapy can make a difference to meet patients’ needs. Usual systemic routes can be travelled by Nanofitins®, but their intrinsic properties make them amenable to other routes, such as oral route and pulmonary delivery.

Website
Key information

–  Therapeutic areas: Infectiology, Oncology, CNS disorders, Inflammatory diseases

–  Based in: Nantes (FRANCE)

–  Employees: 11 -50

–  Created in: 2010